HEPA יחס מהיר Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals (HEPA) develops therapies for chronic liver pathologies, leveraging strict financial management and protected patents. The high standing of its team of biochemists and analysts is sustained through the funding of ambitious scientific research. This price chart, where the indicator stands at 0.00, accounts for current R&D expenditures while anticipating new clinical trial results for the treatment of severe diseases.

The ratio reacts instantaneously to changes in cash balances and accounts receivable, excluding illiquid inventories from the calculation. This metric determines the company's ability to settle short-term obligations without selling goods, where excess cash may signal low capital efficiency. For the biotech firm Hepion Pharmaceuticals (HEPA), which operates without manufacturing plants, this indicator is critical for assessing survival during the clinical trial stage. The dynamics of the quick ratio reflect the actual financial runway of the laboratories.